Pyxis Oncology
PYXS
48 hedge funds and large institutions have $24.6M invested in Pyxis Oncology in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 16 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
2% more funds holding
Funds holding: 47 → 48 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.89% less ownership
Funds ownership: 28% → 25.11% (-2.9%)
41% less capital invested
Capital invested by funds: $41.5M → $24.6M (-$16.9M)
Top Buyers
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$601K |
| 2 |
Renaissance Technologies
New York
|
+$504K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$368K |
| 4 |
Two Sigma Investments
New York
|
+$344K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$340K |
Top Sellers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.09M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.01M |
| 4 |
Morgan Stanley
New York
|
-$533K |
| 5 |
Barclays
London,
United Kingdom
|
-$474K |
PYXS Hedge Fund Activity: Q2 2023 in Review
48 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2023, worth a combined $24.6M — down 41% from $41.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PYXS positions and 16 closed out — a net gain of 1 holder — while 18 added to existing stakes and 7 trimmed.
The largest buyer was ExodusPoint Capital Management, adding an estimated $601K. The largest seller was Tang Capital Management, cutting an estimated $2.2M.
- 48 institutional investors held Pyxis Oncology (PYXS) as of Q2 2023, up from 47 in Q1 2023.
- Funds reported $24.6M of Pyxis Oncology stock for Q2 2023, down 41% quarter-over-quarter.
- 17 funds opened new Pyxis Oncology positions in Q2 2023 and 16 closed out, a net change of +1 holder.
- The largest Pyxis Oncology buyer in Q2 2023 was ExodusPoint Capital Management, an estimated $601K added.
- The largest Pyxis Oncology seller in Q2 2023 was Tang Capital Management, an estimated $2.2M sold.
Based on aggregated 13F filings for Q2 2023.